Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Neurofilaments in pre-symptomatic ALS and the impact of genotype.

Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug 21:1-11. doi: 10.1080/21678421.2019.1646769. [Epub ahead of print]

PMID:
31432691
2.

Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS.

Manzo E, Lorenzini I, Barrameda D, O'Conner AG, Barrows JM, Starr A, Kovalik T, Rabichow BE, Lehmkuhl EM, Shreiner DD, Joardar A, Liévens JC, Bowser R, Sattler R, Zarnescu DC.

Elife. 2019 Jun 10;8. pii: e45114. doi: 10.7554/eLife.45114.

3.

RNA Nucleocytoplasmic Transport Defects in Neurodegenerative Diseases.

Boehringer A, Bowser R.

Adv Neurobiol. 2018;20:85-101. doi: 10.1007/978-3-319-89689-2_4. Review.

PMID:
29916017
4.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

5.

Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis.

Bakkar N, Kovalik T, Lorenzini I, Spangler S, Lacoste A, Sponaugle K, Ferrante P, Argentinis E, Sattler R, Bowser R.

Acta Neuropathol. 2018 Feb;135(2):227-247. doi: 10.1007/s00401-017-1785-8. Epub 2017 Nov 13.

6.

ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export.

Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, Bowser R.

Sci Rep. 2017 Nov 6;7(1):14529. doi: 10.1038/s41598-017-14924-6.

7.

Biomarkers in Neurodegenerative Diseases.

Jeromin A, Bowser R.

Adv Neurobiol. 2017;15:491-528. doi: 10.1007/978-3-319-57193-5_20. Review.

PMID:
28674995
8.

Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers.

Finch NA, Wang X, Baker MC, Heckman MG, Gendron TF, Bieniek KF, Wuu J, DeJesus-Hernandez M, Brown PH, Chew J, Jansen-West KR, Daughrity LM, Nicholson AM, Murray ME, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Petrucelli L, Boeve BF, Graff-Radford NR, Asmann YW, Dickson DW, Benatar M, Bowser R, Boylan KB, Rademakers R, van Blitterswijk M.

Neurol Genet. 2017 Jun 7;3(4):e161. doi: 10.1212/NXG.0000000000000161. eCollection 2017 Aug.

9.

Regulation of the ubiquitylation and deubiquitylation of CREB-binding protein modulates histone acetylation and lung inflammation.

Wei J, Dong S, Bowser RK, Khoo A, Zhang L, Jacko AM, Zhao Y, Zhao J.

Sci Signal. 2017 Jun 13;10(483). pii: eaak9660. doi: 10.1126/scisignal.aak9660.

10.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

11.

Optical barcoding of PLGA for multispectral analysis of nanoparticle fate in vivo.

Medina DX, Householder KT, Ceton R, Kovalik T, Heffernan JM, Shankar RV, Bowser RP, Wechsler-Reya RJ, Sirianni RW.

J Control Release. 2017 May 10;253:172-182. doi: 10.1016/j.jconrel.2017.02.033. Epub 2017 Mar 3.

12.

Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Vu LT, Bowser R.

Neurotherapeutics. 2017 Jan;14(1):119-134. doi: 10.1007/s13311-016-0503-x. Review.

13.

Expression of Carbonic Anhydrase I in Motor Neurons and Alterations in ALS.

Liu X, Lu D, Bowser R, Liu J.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1820.

14.

Destabilization of Lysophosphatidic Acid Receptor 1 Reduces Cytokine Release and Protects Against Lung Injury.

Zhao J, Wei J, Dong S, Bowser RK, Zhang L, Jacko AM, Zhao Y.

EBioMedicine. 2016 Aug;10:195-203. doi: 10.1016/j.ebiom.2016.07.020. Epub 2016 Jul 18.

15.

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.

Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, de Carvalho M, Costa J, van Damme P, Gray E, Grosskreutz J, Hernández-Barral M, Herukka SK, Huss A, Jeromin A, Kirby J, Kuzma-Kozakiewicz M, Amador Mdel M, Mora JS, Morelli C, Muckova P, Petri S, Poesen K, Rhode H, Rikardsson AK, Robberecht W, Rodríguez Mahillo AI, Shaw P, Silani V, Steinacker P, Turner MR, Tüzün E, Yetimler B, Ludolph AC, Otto M.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):404-13. doi: 10.3109/21678421.2016.1167913. Epub 2016 Apr 11.

PMID:
27415180
16.

Immunoprecipitation and mass spectrometry defines an extensive RBM45 protein-protein interaction network.

Li Y, Collins M, An J, Geiser R, Tegeler T, Tsantilas K, Garcia K, Pirrotte P, Bowser R.

Brain Res. 2016 Sep 15;1647:79-93. doi: 10.1016/j.brainres.2016.02.047. Epub 2016 Mar 12. Review.

17.

Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.

Henninger N, Bouley J, Sikoglu EM, An J, Moore CM, King JA, Bowser R, Freeman MR, Brown RH Jr.

Brain. 2016 Apr;139(Pt 4):1094-105. doi: 10.1093/brain/aww001. Epub 2016 Feb 11.

18.

Reply.

Rutkove SB, Shefner JM, Bowser R, Benatar M.

Ann Neurol. 2016 Feb;79(2):334. doi: 10.1002/ana.24586. Epub 2016 Jan 19. No abstract available.

PMID:
26705262
19.

Sustainability in a Hospital-Based Biobank and University-Based DNA Biorepository: Strategic Roadmaps.

Seiler CY, Eschbacher J, Bowser R, LaBaer J.

Biopreserv Biobank. 2015 Dec;13(6):401-9. doi: 10.1089/bio.2015.0076.

20.

Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.

Collins MA, An J, Hood BL, Conrads TP, Bowser RP.

J Proteome Res. 2015 Nov 6;14(11):4486-501. doi: 10.1021/acs.jproteome.5b00804. Epub 2015 Oct 8.

21.

RBM45 homo-oligomerization mediates association with ALS-linked proteins and stress granules.

Li Y, Collins M, Geiser R, Bakkar N, Riascos D, Bowser R.

Sci Rep. 2015 Sep 22;5:14262. doi: 10.1038/srep14262.

22.

To travel or not to travel: The modern day struggle of the academic researcher.

Rutkove SB, Shefner JM, Bowser R, Benatar M.

Ann Neurol. 2015 Nov;78(5):667-9. doi: 10.1002/ana.24516. Epub 2015 Sep 18. No abstract available.

PMID:
26343928
23.

Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?

Smith R, Myers K, Ravits J, Bowser R.

Med Hypotheses. 2015 Nov;85(5):576-83. doi: 10.1016/j.mehy.2015.07.014. Epub 2015 Jul 20.

24.

Total protein is an effective loading control for cerebrospinal fluid western blots.

Collins MA, An J, Peller D, Bowser R.

J Neurosci Methods. 2015 Aug 15;251:72-82. doi: 10.1016/j.jneumeth.2015.05.011. Epub 2015 May 22.

25.

Letter to the editor on "Exposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosis".

Malek AM, Barchowsky A, Bowser R, Heiman-Patterson T, Lacomis D, Rana S, Youk A, Talbott EO.

Environ Pollut. 2015 Dec;207:432-3. doi: 10.1016/j.envpol.2015.05.014. Epub 2015 May 19. No abstract available.

PMID:
26002179
26.

RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1.

Bakkar N, Kousari A, Kovalik T, Li Y, Bowser R.

Mol Cell Biol. 2015 Jul;35(14):2385-99. doi: 10.1128/MCB.00087-15. Epub 2015 May 4.

27.

Race and Rationing.

Bowser R.

Health Matrix Clevel. 2015;25:87-107. No abstract available.

PMID:
29485841
28.

Exposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosis.

Malek AM, Barchowsky A, Bowser R, Heiman-Patterson T, Lacomis D, Rana S, Ada Youk, Talbott EO.

Environ Pollut. 2015 Feb;197:181-186. doi: 10.1016/j.envpol.2014.12.010. Epub 2014 Dec 23.

PMID:
25544309
29.

Focal adhesion kinase-mediated activation of glycogen synthase kinase 3β regulates IL-33 receptor internalization and IL-33 signaling.

Zhao J, Wei J, Bowser RK, Traister RS, Fan MH, Zhao Y.

J Immunol. 2015 Jan 15;194(2):795-802. doi: 10.4049/jimmunol.1401414. Epub 2014 Dec 3.

30.

Use of biomarkers in ALS drug development and clinical trials.

Bakkar N, Boehringer A, Bowser R.

Brain Res. 2015 May 14;1607:94-107. doi: 10.1016/j.brainres.2014.10.031. Epub 2014 Oct 24. Review.

31.

Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis.

Coyne AN, Siddegowda BB, Estes PS, Johannesmeyer J, Kovalik T, Daniel SG, Pearson A, Bowser R, Zarnescu DC.

J Neurosci. 2014 Nov 26;34(48):15962-74. doi: 10.1523/JNEUROSCI.2526-14.2014.

32.

Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells.

Dong S, Khoo A, Wei J, Bowser RK, Weathington NM, Xiao S, Zhang L, Ma H, Zhao Y, Zhao J.

Am J Physiol Cell Physiol. 2014 Nov 1;307(9):C893-9. doi: 10.1152/ajpcell.00132.2014. Epub 2014 Aug 27.

33.

Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface.

Zhao J, Wei J, Bowser RK, Dong S, Xiao S, Zhao Y.

Cell Signal. 2014 Nov;26(11):2406-11. doi: 10.1016/j.cellsig.2014.07.005. Epub 2014 Jul 13.

34.

Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics.

Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD; Northeast ALS Consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):362-70. doi: 10.3109/21678421.2014.908311. Epub 2014 Jul 1.

PMID:
24984169
35.

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.

Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD; ITALSGEN, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chiò A, Traynor BJ.

Nat Neurosci. 2014 May;17(5):664-666. doi: 10.1038/nn.3688. Epub 2014 Mar 30.

36.

F-box protein complex FBXL19 regulates TGFβ1-induced E-cadherin down-regulation by mediating Rac3 ubiquitination and degradation.

Dong S, Zhao J, Wei J, Bowser RK, Khoo A, Liu Z, Luketich JD, Pennathur A, Ma H, Zhao Y.

Mol Cancer. 2014 Apr 1;13:76. doi: 10.1186/1476-4598-13-76.

37.

Biomarker time out.

Petzold A, Bowser R, Calabresi P, Zetterberg H, Uitdehaag BM.

Mult Scler. 2014 Oct;20(12):1560-3. doi: 10.1177/1352458514524999. Epub 2014 Feb 20. Review.

PMID:
24557857
38.

Environmental and occupational risk factors for amyotrophic lateral sclerosis: a case-control study.

Malek AM, Barchowsky A, Bowser R, Heiman-Patterson T, Lacomis D, Rana S, Youk A, Stickler D, Lackland DT, Talbott EO.

Neurodegener Dis. 2014;14(1):31-8. doi: 10.1159/000355344. Epub 2013 Nov 12.

PMID:
24246552
39.

Novel Death Defying Domain in Met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes.

Ma J, Zou C, Guo L, Seneviratne DS, Tan X, Kwon YK, An J, Bowser R, DeFrances MC, Zarnegar R.

Hepatology. 2014 May;59(5):2010-21. doi: 10.1002/hep.26769. Epub 2014 Apr 1.

40.

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X.

Cell Mol Life Sci. 2013 Dec;70(24):4729-45. doi: 10.1007/s00018-013-1415-0. Epub 2013 Jul 18. Review.

41.

Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS.

Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4. doi: 10.3109/21678421.2013.808227. Epub 2013 Jul 8. No abstract available.

PMID:
23834161
42.

Mechanisms, models and biomarkers in amyotrophic lateral sclerosis.

Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, Manfredi G, Maragakis N, Miller RG, Pullman SL, Rutkove SB, Shaw PJ, Shefner J, Fischbeck KH.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:19-32. doi: 10.3109/21678421.2013.778554. Review.

43.

ALS Untangled No. 20: the Deanna protocol.

ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Review. No abstract available.

PMID:
23638638
44.

Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Nukui T, Romkes M, Weissfeld JL.

Cancer Epidemiol. 2013 Aug;37(4):518-22. doi: 10.1016/j.canep.2013.03.020. Epub 2013 Apr 23.

45.

Measurement of cystatin C functional activity in the cerebrospinal fluid of amyotrophic lateral sclerosis and control subjects.

Wilson ME, Boumaza I, Bowser R.

Fluids Barriers CNS. 2013 Mar 15;10(1):15. doi: 10.1186/2045-8118-10-15.

46.

Reactive astrocytes secrete lcn2 to promote neuron death.

Bi F, Huang C, Tong J, Qiu G, Huang B, Wu Q, Li F, Xu Z, Bowser R, Xia XG, Zhou H.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4069-74. doi: 10.1073/pnas.1218497110. Epub 2013 Feb 19.

47.

Retinoid signaling alterations in amyotrophic lateral sclerosis.

Kolarcik CL, Bowser R.

Am J Neurodegener Dis. 2012;1(2):130-45. Epub 2012 Jul 23.

48.

SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM.

JAMA Neurol. 2013 Feb;70(2):201-7. doi: 10.1001/jamaneurol.2013.593.

49.

pNfH is a promising biomarker for ALS.

Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Mar;14(2):146-9. doi: 10.3109/21678421.2012.729596. Epub 2012 Oct 22.

PMID:
23134506
50.

The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.

Collins M, Riascos D, Kovalik T, An J, Krupa K, Krupa K, Hood BL, Conrads TP, Renton AE, Traynor BJ, Bowser R.

Acta Neuropathol. 2012 Nov;124(5):717-32. doi: 10.1007/s00401-012-1045-x. Epub 2012 Sep 21.

Supplemental Content

Loading ...
Support Center